Published 20 December 2004. doi:10.1084/jem.20042004
Rockefeller University Press, 0022-1007 $8.00
JEM, Volume 200, Number 12, 1533-1537
Finding a Place for Tumor-specific T Cells in Targeted Cancer Therapy
Stanley R. Riddell
Clinical Research Division, Fred Hutchinson Cancer Research Center, Department of Medicine, University of Washington, Seattle, WA 98109
Address correspondence to Stanley R. Riddell, Program in Immunology, D3-110, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave. N., Seattle, WA 98109. Phone: (206) 667-5249; Fax: (206) 667-7983; email: sriddell{at}fhcrc.org
Abstract
A goal in cancer therapeutics is to develop targeted modalities that distinguish malignant from normal cells. T cells can discriminate diseased cells based on subtle alterations in peptides displayed in association with MHC molecules at the cell surface. Recent success using the adoptive transfer of tumor-specific T cells has fueled optimism that this approach may find a place as a targeted therapy for some human cancers.

CiteULike
Complore
Connotea
Del.icio.us
Digg
Facebook
Reddit
Technorati
Twitter What's this?
This article has been cited by other articles:
-
Wall, E. M., Milne, K., Martin, M. L., Watson, P. H., Theiss, P., Nelson, B. H.
(2007). Spontaneous Mammary Tumors Differ Widely in Their Inherent Sensitivity to Adoptively Transferred T Cells. Cancer Res.
67: 6442-6450
[Abstract]
[Full Text]
-
Inoue, S., Leitner, W. W., Golding, B., Scott, D.
(2006). Inhibitory effects of B cells on antitumor immunity.. Cancer Res.
66: 7741-7747
[Abstract]
[Full Text]
-
Zhang, T., Barber, A., Sentman, C. L.
(2006). Generation of Antitumor Responses by Genetic Modification of Primary Human T Cells with a Chimeric NKG2D Receptor. Cancer Res.
66: 5927-5933
[Abstract]
[Full Text]